The following is an excerpt.
The business of DNA is undergoing a revolution. We can already get our genes scanned for thebargain-basement price of $99. Soon we’ll be able to have entire genomes sequenced for less than the cost of a MacBook Air. That’s huge considering that not so long ago it cost billions of dollars to map a single genome.
But the ability of scientists, doctors and companies to tell us how our genes might impact our health now hinges on a case being debated by the U.S. Supreme Court, the infamously drawn-out Association for Molecular Pathology v. Myriad Genetics.
Read the full article here: Gene Patents Are Sabotaging the Future of Medicine